Heghine Khachatryan on ITP’s Key Research Gaps: Biomarkers, Fatigue and Thrombosis Risk
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post by ITP Support Association on LinkedIn:
“One important research priority in ITP is understanding disease heterogeneity and treatment response.
Which immunological and clinical biomarkers can predict progression to chronic or refractory ITP and guide personalized therapy (steroids, TPO-RAs, rituximab, fostamatinib)?
In addition, fatigue remains a major unmet need in ITP and often persists despite adequate platelet counts. Understanding its inflammatory and immune mechanisms would have a major impact on patient quality of life.
Finally, the balance between bleeding and thrombosis risk in ITP—especially in patients treated with TPO-receptor agonists and during pregnancy—requires further real-world and prospective studies.”
Quoting ITP Support Association’s post:
“Got an idea for ITP research?
We’ve funded studies on fatigue, pregnancy, MRI, bone marrow, and more. Now we want YOUR input!
What should researchers explore next in ITP?
Drop your ideas in the comments below You can also email your ideas for research to [email protected] and we will collate all the responses from the comments and emails and discuss with our medical advisory team.”
Stay updated and find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Jul 8, 2026, 11:33Ifeanyichukwu Ifechidere: Haemophilia A and B – From First Diagnosis to the Era of Gene Therapy
-
Jul 8, 2026, 10:29Bringing Hemophilia Care Closer to Communities in Togo – WFH
-
Jul 8, 2026, 10:12Natasha Jolakoski: Completing Advanced Training in Thrombosis and Hemostasis
-
Jul 8, 2026, 09:58Rola Ghasoub: Early Intracranial Hemorrhage Remains the Main Barrier to Cure in Acute Promyelocytic Leukemia
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis
-
Jul 8, 2026, 04:50Reza Bavarsad Shahripour: New AHA Guidance on Cryptogenic Stroke with Reduced Left Ventricular Function
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism